In recent years, there has been a shift from extrapleural pneumonectomy (EPP) toward pleurectomy/decortication (P/D) as the preferred surgical technique. However, we occasionally encounter difficult cases wherein visceral pleurectomy requires conversion to EPP from P/D. We sought to clarify the preoperative risk factors and clinical outcomes associated with conversion to EPP. We compared and analyzed conversion to EPP and P/D between September 2012 and December 2019. Conversion to EPP was decided in case of diffuse tumor invasion to the pulmonary parenchyma or due to failure of decortication. Univariable regression analysis was performed to determine the association of preoperative variables with conversion to EPP. Survival was analyzed by the Kaplan-Meier method and log-rank test. Of the 181 patients who underwent intended P/D, 145 (80.1%) patients underwent P/D and 18 (9.9%) patients underwent conversion to EPP. The sum of 3-level pleural thickness (P < 0.001), maximum of 3-level pleural thickness (P = 0.006), and clinical T stage (P < 0.001) demonstrated association with conversion to EPP. Overall survival and progression-free survival were significantly worse in the conversion to EPP group (median overall survival, 29.2 months vs 57.0 months [P = 0.008]; median progression-free survival, 15.3 months vs 23.2 months [P = 0.005]. Our data show that approximately 1 of every 10 patients with P/D intention converted to EPP. Preoperative pleural thickness and clinical T stage may be risk factors associated with conversion to EPP. The survival rate of conversion to EPP was worse than that of P/D.
Abbreviations:ARDS (acute respiratory distress syndrome), CT (computed tomography), EPP (extrapleural pneumonectomy), eP/D (extended pleurectomy/decortication), FEV1 (force expiratory volume in 1 second), MCR (macroscopic complete resection), MPM (malignant pleural mesothelioma), NAC (neoadjuvant chemotherapy), P/D (pleurectomy/decortication), PFS (progression-free survival), PS (performance status), OR (odds ratio), OS (overall survival)
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Seminars in Thoracic and Cardiovascular Surgery
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Surgical risk and survival associated with less invasive surgery for malignant pleural mesothelioma.Semin Thorac Cardiovasc Surg. 2019; 31: 301-309
- Extrapleural pneumonectomy: Still indicated?.Transl Lung Cancer Res. 2019; 7: 550-555
- Clinical outcomes with recurrence after pleurectomy/decortication for malignant pleural mesothelioma.Ann Thorac Surg. 2020; 109: 1537-1543
- A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.Lung Cancer. 2014; 83: 240-245
- Three decades of experience in the surgical multi-modality management of pleural mesothelioma.Eur J Cardiothorac Surg. 2010; 37: 552-556
- Post-recurrence chemotherapy for mesothelioma patients undergoing extrapleural pneumonectomy.Int J Clin Oncol. 2017; 22: 857-864
- Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma.Ann Thorac Surg. 2015; 99: 472-480
- A feasibility study of induction pemetrexed plus cisplatin followed by pleurectomy/decortication for malignant pleural mesothelioma (Japan Mesothelioma Interest Group 1101 Trial).J Clin Oncol. 2019; 37: S8518
- Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.Ann Oncol. 2004; 15: 257-260
- Pleural thickness after neoadjuvant chemotherapy is a prognostic factor in malignant pleural mesothelioma.J Thorac Cardiovasc Surg. 2019; 157: 404-413
- A proposed system toward standardizing surgical-based treatments for malignant pleural mesothelioma, from the joint national cancer institute-international association for the study of lung cancer-mesothelioma applied research foundation taskforce.J Thorac Oncol. 2019; 14: 1343-1353
- The IASLC Mesothelioma Staging Project: Proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM Classification for Pleural Mesothelioma.J Thorac Oncol. 2016; 11: 2089-2099
- Severity grading of surgical complications.Ann Surg. 2009; 250: 197-198
- A nuanced view of extrapleural pneumonectomy for malignant pleural mesothelioma.Ann Transl Med. 2017; 5: 237
- Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma.J Thorac Oncol. 2012; 7: 737-743
- Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: A 10-year experience.J Thoracic Cardiovasc Surg. 2015; 149: 558-565
- Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma.Ann Thorac Surg. 2012; 93: 1658-1665
- The state of the art in the technical performance of lung-sparing operations for malignant pleural mesothelioma.Semin Thorac Cardiovasc Surg. 2013; 25: 125-143
- The effects of an intentional transition from extrapleural pneumonectomy to extended pleurectomy/decortication.Eur Cardiothorac Surg. 2016; 49: 1632-1641
- Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma.J Thorac Cardiovasc Surg. 2015; 149: 1374-1381
- Preoperative prediction of unresectability in malignant pleural mesothelioma.J Thoracic Cardiovasc Surg. 2019; (Epub ahead of print)https://doi.org/10.1016/j.jtcvs.2019.11.035
- Pleurectomy/decortication versus extrapleural pneumonectomy: A critical choice.J Thorac Dis. 2018; 10: S390-S394
Published online: February 17, 2021
Conflicts of Interest: None.
Date and Number of IRB Approval: The institutional review board at the Hyogo College of Medicine (no. 3437) approved the study on February 25, 2020.
© 2021 Elsevier Inc. All rights reserved.
ScienceDirectAccess this article on ScienceDirect
- Commentary: To Preserve or Not Preserve (The Lung): That Is the MPM QuestionSeminars in Thoracic and Cardiovascular SurgeryVol. 33Issue 3
- PreviewDr Nakamura and colleagues report their experience with conversion to extrapleural pneumonectomy (EPP) during planned extended pleurectomy and decortication (ePD) for patients with malignant pleural mesothelioma (MPM).1 They found that the increase in preoperative tumor thickness at three levels (and T stage) was associated with conversion. Both the assessment of prognostic factors and the conversion strategy warrant discussion.